Advances in the computational landscape for repurposed drugs against COVID-19

被引:18
|
作者
Aronskyy, Illya [1 ]
Masoudi-Sobhanzadeh, Yosef [2 ]
Cappuccio, Antonio [1 ]
Zaslavsky, Elena [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA
[2] Tabriz Univ Med Sci, Res Ctr Pharmaceut Nanotechnol, Biomed Inst, Tabriz, Iran
基金
美国国家卫生研究院;
关键词
Computational drug repurposing; COVID-19; SARS-CoV-2; Docking and molecular dynamics; Structure-guided machine learning; Virus-host interaction network analysis; CORONAVIRUS; DOCKING; COMPLEMENT; SARS-COV-2; KNOWLEDGE; HELICASE; DATABASE; BINDING; DESIGN;
D O I
10.1016/j.drudis.2021.07.026
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The COVID-19 pandemic has caused millions of deaths and massive societal distress worldwide. Therapeutic solutions are urgently needed, but de novo drug development remains a lengthy process. One promising alternative is computational drug repurposing, which enables the prioritization of existing compounds through fast in silico analyses. Recent efforts based on molecular docking, machine learning, and network analysis have produced actionable predictions. Some predicted drugs, targeting viral proteins and pathological host pathways are undergoing clinical trials. Here, we review this work, highlight drugs with high predicted efficacy and classify their mechanisms of action. We discuss the strengths and limitations of the published methodologies and outline possible future directions. Finally, we curate a list of COVID-19 data portals and other repositories that could be used to accelerate future research.
引用
收藏
页码:2800 / 2815
页数:16
相关论文
共 50 条
  • [11] Biggest COVID-19 trial tests repurposed drugs first
    Dolgin, Elie
    NATURE BIOTECHNOLOGY, 2020, 38 (05) : 510 - 511
  • [12] Efficacy of repurposed antiviral drugs: Lessons from COVID-19
    Martinez, Miguel Angel
    DRUG DISCOVERY TODAY, 2022, 27 (07) : 1954 - 1960
  • [13] Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics
    Chatterjee, Bhaswati
    Thakur, Suman S.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [14] Targeting COVID-19 in Parkinson's Patients: Drugs Repurposed
    Anwar, Firoz
    Naqvi, Salma
    Al-Abbasi, Fahad A.
    Neelofar, Nauroz
    Kumar, Vikas
    Sahoo, Ankit
    Kamal, Mohammad Amjad
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (12) : 2392 - 2408
  • [16] Repurposed drugs and nutraceuticals targeting envelope protein: A possible therapeutic strategy against COVID-19
    Das, Gourab
    Das, Troyee
    Chowdhury, Nilkanta
    Chatterjee, Durbadal
    Bagchi, Angshuman
    Ghosh, Zhumur
    GENOMICS, 2021, 113 (01) : 1129 - 1140
  • [17] Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19
    Bibi, Nousheen
    Gul, Sana
    Ali, Johar
    Kamal, Mohammad Amjad
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 885
  • [18] Study Aims to Identify Drugs That Could Be Repurposed for COVID-19
    Rubin, Rita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (20): : 2019 - 2019
  • [19] Repurposed drugs for COVID-19: threshold and proof requirements for trials
    Paul, Mical
    Kalil, Andre C.
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (12) : 1716 - 1717
  • [20] Impact of Liver Functions by Repurposed Drugs for COVID-19 Treatment
    Zhang, Rongzhi
    Wang, Qiang
    Yang, Jianshe
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (04) : 748 - 756